🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are on the rise worldwide, with estimates suggesting over 82 million new cases each year. Notably increased rates are observed in Africa and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary development in the context of rising global incidence, increasing antimicrobial resistance and the extremely scarce therapeutic options currently available.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring found that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

Zoliflodacin, alternatively called a brand name, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is also used to treat UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This authorization signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Data and Global Access

Based on data published in a major medical journal, the new drug eradicated the vast majority of cases of the STI. This puts it on an equal footing with the typical regimen, which uses a dual-drug approach. The trial involved hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to license and sell the drug in many low-income and middle-income countries.

Clinicians on the front lines have voiced optimism. Having a one-pill regimen like this is described as a "critical tool" for managing the epidemic. This is considered essential to alleviate the strain of the disease for people and to prevent the spread of untreatable gonorrhoea worldwide.